2. Academic Validation
  3. A Glucosylated BODIPY Uses the GLUT Channel to Target Cancer Cells in In Vitro and In Vivo Models

A Glucosylated BODIPY Uses the GLUT Channel to Target Cancer Cells in In Vitro and In Vivo Models

  • ACS Omega. 2025 Nov 7;10(45):54217-54223. doi: 10.1021/acsomega.5c06410.
Marta Turati 1,  Giacomo Biagiotti 2,  Cosetta Ravelli 1,  Chiara Tobia 1,  Jacopo Cardellini 2,  Luca Mignani 1,  Jacopo Tricomi 2,  Debora Berti 2,  Stefano Cicchi 2,  Barbara Richichi 2,  Roberto Ronca 1
Affiliations

Affiliations

  • 1 Department of Molecular and Translational Medicine, University of Brescia, Brescia 25121, Italy.
  • 2 Department of Chemistry "Ugo Schiff", University of Firenze, Via della Lastruccia 13, Sesto Fiorentino, Fi 50019, Italy.
PMID: 41280800 DOI: 10.1021/acsomega.5c06410
Abstract

The conjugation of fluorescent probes to tumor-targeting molecules represents a promising strategy for the development of precision Cancer bioimaging and treatment. Among the different tumor-targeting strategies, the use of d-glucose residues, which exploit the high energy demand of Cancer cells, can enable recognition by a broad spectrum of tumors, thus overcoming limitations related to Cancer heterogeneity. In this study, we combined the distinctive optical properties of BODIPY-based probes with the known tumor-targeting abilities of d-glucose. We report on the characterization of a glucosylated BODIPY, named Glc-BODIPY, and its ability to target different Cancer cell types in both in vitro and in vivo models.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-19331
    99.93%, Glut1 Inhibitor